SEC Charges Three Former Executives of Pharmacy Startup Medly Health Inc. with Defrauding Investors
summary
Former Medly Health executives Marg Patel, Robert Horowitz, and Chintankumar Bhatt were charged by the SEC for defrauding investors of over $170 million through overstated revenues.
paragraph
The SEC charged Medly Health's former CEO, CFO, and Head of Rx Operations with violating antifraud securities provisions during capital raising efforts that netted over $170 million. The defendants allegedly overstated revenue by ignoring accounting irregularities and using millions of dollars in fake prescriptions. The SEC is seeking permanent injunctions, civil penalties, disgorgement, and officer-and-director bars against all three individuals.
narrative
The SEC has charged former Medly Health Inc. executives Marg Patel, Robert Horowitz, and Chintankumar Bhatt with defrauding investors during capital raising efforts that netted the company over $170 million. Between February 2021 and August 2022, Patel and Horowitz allegedly provided investors with fraudulent financial information that overstated revenue. This deception was facilitated by Bhatt, who entered millions of dollars worth of fake prescriptions into the company's systems. The complaint alleges that Patel and Horowitz were aware of significant accounting irregularities and employee complaints regarding inaccurate revenue reporting. The defendants face charges for violating antifraud provisions of securities laws, with Bhatt also charged with aiding and abetting. The SEC is seeking permanent injunctions, civil money penalties, disgorgement, and officer-and-director bars against all three defendants.
Classified accounting-fraud(confidence 95%). EDGAR detection: forms 10-K/10-Q/8-K/NT 10-K· recall 80% / precision 48%. detection rule →
Statutes
15 U.S.C. § 78j(b)17 C.F.R. § 240.10b-5
Parties
alex vasilescumillions of dollars’ worth of fake prescriptions into the company’s systemssec’s complaintSecurities and Exchange Commissionsignificant accounting irregularitiesthe sec’s investigation
Keywords
investorspatel horowitzsecpharmacy startupstartup medlymedly healthdefrauding investorsformermedlypatelhorowitzbhattformer executivesexecutives pharmacymarshall molavi
Exhibits & Attached Documents (1)
Extracted insights
Dollar amounts 1
- $170.00M $170 million $100M–$1B
Entities 6
- person alex vasilescu
- company millions of dollars’ worth of fake prescriptions into the company’s systems
- agency sec’s complaint
- agency Securities and Exchange Commission
- person significant accounting irregularities
- agency the sec’s investigation
Triples 12
- Securities and Exchange Commission charged Marg Patel, Robert Horowitz, and Chintankumar Bhatt
- SEC’s complaint alleges Patel and Horowitz knew of significant accounting irregularities
- Patel and Horowitz failed to correct significant accounting irregularities
- Bhatt entered millions of dollars’ worth of fake prescriptions into the company’s systems
- SEC’s complaint alleges defendants harmed investors by misleading them about the company’s revenues
- Bhatt made up fake prescription orders to increase revenue numbers
- SEC’s complaint charges Patel, Horowitz, and Bhatt with violating the antifraud provisions of the securities laws
- SEC’s complaint charges Bhatt with aiding and abetting Patel’s and Horowitz’s primary securities law violations
- The SEC’s investigation is being conducted by Suzanne M. Bettis, Heather Marshall Molavi, Lisa Knoop, and Christopher M. Colorado of the New York Regional Office
- The SEC’s investigation is being supervised by Judith Weinstock, Mr. Pollock, and Antonia Apps
- The litigation will be led by Mr. Colorado, Ms. Bettis, and Ms. Marshall Molavi
- The litigation is under the supervision of Alex Vasilescu
PDF (from attached: complaint)
Text layers
Extracted body text (2,274c)
The Securities and Exchange Commission today charged now-defunct digital pharmacy startup Medly Health Inc’s. co-founder and former CEO, Marg Patel, former CFO, Robert Horowitz, and former Head of Rx Operations, Chintankumar Bhatt, with defrauding investors in connection with capital raising efforts that netted the company over $170 million. According to the SEC’s complaint, from at least February 2021 through August 2022, Patel and Horowitz provided financial information to existing and prospective investors that fraudulently overstated Medly’s revenue due in part to millions of dollars’ worth of fake prescriptions entered into the company’s systems by Bhatt. The SEC’s complaint alleges, among other things, that Patel and Horowitz knew of, but failed to correct, significant accounting irregularities and were aware of several reports and complaints by employees that the revenue reported in Medly’s financial statements to investors was inaccurate. “The alleged facts of this case demonstrate significant corporate malfeasance,” said Sheldon L. Pollock, Associate Director of Enforcement in the New York Regional Office. “We allege the defendants harmed investors by misleading them about the company’s revenues, with one defendant going as far as making up fake prescription orders to increase revenue numbers. Startups that seek to raise capital from investors through deceitful conduct remain a continued focus for the Commission.” The SEC’s complaint, filed in the U.S. District Court for the Eastern District of New York, charges Patel, Horowitz, and Bhatt with violating the antifraud provisions of the securities laws and charges Bhatt with aiding and abetting Patel’s and Horowitz’s primary securities law violations. The complaint seeks permanent injunctions, civil money penalties, disgorgement, prejudgment interest, and officer-and-director bars against all three defendants. The SEC’s investigation is ongoing and is being conducted by Suzanne M. Bettis, Heather Marshall Molavi, Lisa Knoop, and Christopher M. Colorado of the New York Regional Office. It is being supervised by Judith Weinstock, Mr. Pollock, and Antonia Apps. The litigation will be led by Mr. Colorado, Ms. Bettis, and Ms. Marshall Molavi, under the supervision of Alex Vasilescu.
OCR text (2,274c · html-text · 99% conf)
The Securities and Exchange Commission today charged now-defunct digital pharmacy startup Medly Health Inc’s. co-founder and former CEO, Marg Patel, former CFO, Robert Horowitz, and former Head of Rx Operations, Chintankumar Bhatt, with defrauding investors in connection with capital raising efforts that netted the company over $170 million. According to the SEC’s complaint, from at least February 2021 through August 2022, Patel and Horowitz provided financial information to existing and prospective investors that fraudulently overstated Medly’s revenue due in part to millions of dollars’ worth of fake prescriptions entered into the company’s systems by Bhatt. The SEC’s complaint alleges, among other things, that Patel and Horowitz knew of, but failed to correct, significant accounting irregularities and were aware of several reports and complaints by employees that the revenue reported in Medly’s financial statements to investors was inaccurate. “The alleged facts of this case demonstrate significant corporate malfeasance,” said Sheldon L. Pollock, Associate Director of Enforcement in the New York Regional Office. “We allege the defendants harmed investors by misleading them about the company’s revenues, with one defendant going as far as making up fake prescription orders to increase revenue numbers. Startups that seek to raise capital from investors through deceitful conduct remain a continued focus for the Commission.” The SEC’s complaint, filed in the U.S. District Court for the Eastern District of New York, charges Patel, Horowitz, and Bhatt with violating the antifraud provisions of the securities laws and charges Bhatt with aiding and abetting Patel’s and Horowitz’s primary securities law violations. The complaint seeks permanent injunctions, civil money penalties, disgorgement, prejudgment interest, and officer-and-director bars against all three defendants. The SEC’s investigation is ongoing and is being conducted by Suzanne M. Bettis, Heather Marshall Molavi, Lisa Knoop, and Christopher M. Colorado of the New York Regional Office. It is being supervised by Judith Weinstock, Mr. Pollock, and Antonia Apps. The litigation will be led by Mr. Colorado, Ms. Bettis, and Ms. Marshall Molavi, under the supervision of Alex Vasilescu.